1 / 2

Enasidenib(Idhifa)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Celgene

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Enasidenib(Idhifa) Instructions:Uses,Dosage, Side Effects

IDHIFA, with the generic name enasidenib, is an oral isocitrate dehydrogenase-2 (IDH2) enzyme inhibitor. It is formulated as film-coated tablets available in 50 mg and 100 mg strengths. The drug functions by targeting mutant IDH2 variants, leading to a reduction in the oncometabolite 2-hydroxyglutarate (2-HG) and promoting differentiation of myeloid cells. It is marketed by Bristol Myers Squibb Company.

Generic name

Enasidenib(Idhifa)

English name

Enasidenib

Alternative Names

Idhifa

Drug prices

Indications

IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved companion diagnostic test.

Therapeutic Target

Mutant Isocitrate Dehydrogenase 2 (IDH2) enzyme. IDHIFA specifically inhibits the mutant IDH2 variants R140Q, R172S, and R172K.

Active Ingredients

Enasidenib

Dosage form

TABLET

specifications

100mg * 30 tablets/box, 50mg * 30 tablets/box

Description

Dosage and Administration

The recommended dosage is 100 mg taken orally once daily, with or without food.

CATEGORY NAVIGATION

RECOMMENDED ARTICLES

Enasidenib Dosage and Administration, Recommended Dose

Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult patients with...

Monday, January 5th, 2026, 11:28

Side Effects of Enasidenib

Enasidenib is a targeted therapeutic agent for the treatment of relapsed or refractory acute myeloid leukemia (AML)...

Monday, January 5th, 2026, 11:24

What are the Precautions for Enasidenib Use?

Enasidenib is an oral targeted therapy drug for adult patients with relapsed or refractory acute myeloid leukemia...

Monday, January 5th, 2026, 11:21

What are the indications for Enasidenib?

Enasidenib is an oral targeted therapy drug, marketed under the brand name IDHIFA®, which was first approved for...

Monday, January 5th, 2026, 11:16

Purchase Channels for Enasidenib

Enasidenib is a targeted drug for relapsed or refractory acute myeloid leukemia (AML) with IDH2...

Monday, January 5th, 2026, 11:12

Side Effects of Enasidenib

Enasidenib is a targeted therapy for adult patients with relapsed or refractory acute myeloid leukemia (AML)...

Tuesday, December 23rd, 2025, 10:24

Departments

Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology

Contact Medical Consultant

Global Drug Search

Clinical recruitment

overseas medical treatment

Remote consultation

Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.

Click to submit medical consultant

haiousales@gmail.com

Welcome To Consult